Blueshift Asset Management LLC Has $682,000 Stock Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Blueshift Asset Management LLC raised its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 14.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,343 shares of the company’s stock after buying an additional 537 shares during the period. Blueshift Asset Management LLC’s holdings in TransMedics Group were worth $682,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Quantbot Technologies LP boosted its holdings in shares of TransMedics Group by 601.9% during the 3rd quarter. Quantbot Technologies LP now owns 19,738 shares of the company’s stock valued at $3,099,000 after acquiring an additional 16,926 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in TransMedics Group by 3.7% in the third quarter. The Manufacturers Life Insurance Company now owns 18,473 shares of the company’s stock valued at $2,900,000 after purchasing an additional 657 shares during the last quarter. Bank of Montreal Can boosted its stake in shares of TransMedics Group by 1.2% during the third quarter. Bank of Montreal Can now owns 69,973 shares of the company’s stock valued at $11,136,000 after purchasing an additional 809 shares in the last quarter. Algert Global LLC grew its holdings in shares of TransMedics Group by 119.1% during the third quarter. Algert Global LLC now owns 39,048 shares of the company’s stock worth $6,131,000 after purchasing an additional 21,223 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of TransMedics Group by 2.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock valued at $42,656,000 after buying an additional 6,634 shares during the period. Institutional investors own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on TMDX shares. Robert W. Baird dropped their price target on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating for the company in a research note on Tuesday, October 29th. Canaccord Genuity Group dropped their price target on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. Oppenheimer decreased their price objective on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating for the company in a research report on Tuesday, October 29th. Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Finally, Stephens upped their price target on shares of TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Two investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $131.80.

Insider Buying and Selling

In related news, Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the sale, the director now owns 732 shares in the company, valued at $61,158.60. This represents a 90.22 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $153.42, for a total value of $1,323,247.50. Following the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at $9,457,269.06. This trade represents a 12.27 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 26,958 shares of company stock worth $3,470,328 in the last ninety days. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $87.11 on Thursday. The firm has a market capitalization of $2.92 billion, a P/E ratio of 92.67 and a beta of 2.08. The firm’s 50-day moving average price is $114.84 and its 200-day moving average price is $136.79. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a 1-year low of $67.77 and a 1-year high of $177.37.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. During the same period last year, the company posted ($0.12) earnings per share. The firm’s quarterly revenue was up 63.7% compared to the same quarter last year. Equities research analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.